BACKGROUND: Conservative surgery (CS) and radiation therapy (RT) as an alternative to mastectomy is controversial in patients with two or more lesions in the same breast. The authors reviewed their experience with CS and RT in the management of patients with synchronous ipsilateral breast cancer (SIBC). METHODS: Of 1060 patients treated with CS and RT at the authors' facilities before December 1988, 13 (1.2%) presented with SIBC. All lesions were identified macroscopically and confirmed microscopically as carcinoma. After excision, patients were treated with radiation to the breast for a median tumor bed dose of 65 Gy, and regional lymphatics were treated as clinically indicated to a median dose of 48 Gy. These cases were retrospectively reviewed. RESULTS: As of February 1992, with a median follow-up of 71 months, the 5-year actuarial survival rate of the 13 patients was 81%. Three of the 13 (23%) had an ipsilateral breast recurrence, resulting in a 72-month actuarial breast recurrence rate of 25%, compared with a rate of 12% in our singular lesion population. Two of these patients remain alive, no evidence of disease at 135 and 93 months after diagnosis. The third patient had chest wall progression and died with metastatic disease at 64 months. Invasive lobular histology and three separate lesions were identified in two of the three patients with subsequent local recurrence. CONCLUSIONS: The local recurrence rate in conservatively treated patients with SIBC is greater than that seen in patients with single lesions, but because of the small sample size, significant conclusions are not possible. Although the data are limited on this subject, these results support consideration of CS and RT as an option in the management of selected patients who favor a breast conservation management approach.
BACKGROUND: Conservative surgery (CS) and radiation therapy (RT) as an alternative to mastectomy is controversial in patients with two or more lesions in the same breast. The authors reviewed their experience with CS and RT in the management of patients with synchronous ipsilateral breast cancer (SIBC). METHODS: Of 1060 patients treated with CS and RT at the authors' facilities before December 1988, 13 (1.2%) presented with SIBC. All lesions were identified macroscopically and confirmed microscopically as carcinoma. After excision, patients were treated with radiation to the breast for a median tumor bed dose of 65 Gy, and regional lymphatics were treated as clinically indicated to a median dose of 48 Gy. These cases were retrospectively reviewed. RESULTS: As of February 1992, with a median follow-up of 71 months, the 5-year actuarial survival rate of the 13 patients was 81%. Three of the 13 (23%) had an ipsilateral breast recurrence, resulting in a 72-month actuarial breast recurrence rate of 25%, compared with a rate of 12% in our singular lesion population. Two of these patients remain alive, no evidence of disease at 135 and 93 months after diagnosis. The third patient had chest wall progression and died with metastatic disease at 64 months. Invasive lobular histology and three separate lesions were identified in two of the three patients with subsequent local recurrence. CONCLUSIONS: The local recurrence rate in conservatively treated patients with SIBC is greater than that seen in patients with single lesions, but because of the small sample size, significant conclusions are not possible. Although the data are limited on this subject, these results support consideration of CS and RT as an option in the management of selected patients who favor a breast conservation management approach.
Authors: Kari M Rosenkranz; Karla Ballman; Linda McCall; Charlotte Kubicky; Laurie Cuttino; Huong Le-Petross; Kelly K Hunt; Armando Giuliano; Kimberly J Van Zee; Bruce Haffty; Judy C Boughey Journal: Ann Surg Oncol Date: 2018-07-09 Impact factor: 5.344
Authors: Kari M Rosenkranz; Karla Ballman; Linda McCall; Colleen McCarthy; Charlotte D Kubicky; Laurie Cuttino; Kelly K Hunt; Armando Giuliano; Kimberly J Van Zee; Bruce Haffty; Judy C Boughey Journal: Ann Surg Oncol Date: 2020-07-22 Impact factor: 5.344
Authors: Y A Masannat; A Agrawal; L Maraqa; M Fuller; S K Down; Ssk Tang; D Pang; M Kontos; L Romics; S D Heys Journal: Ann R Coll Surg Engl Date: 2019-09-06 Impact factor: 1.891
Authors: Siobhan P Lynch; Xiudong Lei; Limin Hsu; Funda Meric-Bernstam; Thomas A Buchholz; Hong Zhang; Gabriel N Hortobágyi; Ana M Gonzalez-Angulo; Vicente Valero Journal: Oncologist Date: 2013-10-17